Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
|Articles|June 12, 2008
Allergan set to unveil eyelash-growing product
Irvine, Calif. - Allergan is planning to file a New Drug Application to the FDA by end of the third quarter of 2008 for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth, according to a press release.
Advertisement
Irvine, Calif.
- Allergan is planning to file a New Drug Application to the FDA by end of the third quarter of 2008 for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth, according to a press release.
Allergan has completed a clinical trial, demonstrating that bimatoprost, the active ingredient in Allergan's glaucoma drug, Lumigan. The product will likely be launched next summer, pending the FDA approval of the application.
In November, Allergan sued a a number of cosmetic companies selling "eyelash conditioners" for infringing on a patent covering both bimatoprost and related compounds called prostaglandins, according to the Wall Street Journal.
The company expects the product will exceed $500 million in global sales.
Advertisement
Related to this article
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
3
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5